Cargando…
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811892/ https://www.ncbi.nlm.nih.gov/pubmed/20003352 http://dx.doi.org/10.1186/cc8208 |
_version_ | 1782176804842242048 |
---|---|
author | Bermejo-Martin, Jesus F Ortiz de Lejarazu, Raul Pumarola, Tomas Rello, Jordi Almansa, Raquel Ramírez, Paula Martin-Loeches, Ignacio Varillas, David Gallegos, Maria C Serón, Carlos Micheloud, Dariela Gomez, Jose Manuel Tenorio-Abreu, Alberto Ramos, María J Molina, M Lourdes Huidobro, Samantha Sanchez, Elia Gordón, Mónica Fernández, Victoria del Castillo, Alberto Marcos, Ma Ángeles Villanueva, Beatriz López, Carlos Javier Rodríguez-Domínguez, Mario Galan, Juan-Carlos Cantón, Rafael Lietor, Aurora Rojo, Silvia Eiros, Jose M Hinojosa, Carmen Gonzalez, Isabel Torner, Nuria Banner, David Leon, Alberto Cuesta, Pablo Rowe, Thomas Kelvin, David J |
author_facet | Bermejo-Martin, Jesus F Ortiz de Lejarazu, Raul Pumarola, Tomas Rello, Jordi Almansa, Raquel Ramírez, Paula Martin-Loeches, Ignacio Varillas, David Gallegos, Maria C Serón, Carlos Micheloud, Dariela Gomez, Jose Manuel Tenorio-Abreu, Alberto Ramos, María J Molina, M Lourdes Huidobro, Samantha Sanchez, Elia Gordón, Mónica Fernández, Victoria del Castillo, Alberto Marcos, Ma Ángeles Villanueva, Beatriz López, Carlos Javier Rodríguez-Domínguez, Mario Galan, Juan-Carlos Cantón, Rafael Lietor, Aurora Rojo, Silvia Eiros, Jose M Hinojosa, Carmen Gonzalez, Isabel Torner, Nuria Banner, David Leon, Alberto Cuesta, Pablo Rowe, Thomas Kelvin, David J |
author_sort | Bermejo-Martin, Jesus F |
collection | PubMed |
description | INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with nvH1N1. METHODS: We profiled 29 cytokines and chemokines and evaluated the haemagglutination inhibition activity as quantitative and qualitative measurements of host immune responses in serum obtained during the first five days after symptoms onset, in two cohorts of nvH1N1 infected patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). A group of healthy donors was included as control (n = 15). Differences in levels of mediators between groups were assessed by using the non parametric U-Mann Whitney test. Association between variables was determined by calculating the Spearman correlation coefficient. Viral load was performed in serum by using real-time PCR targeting the neuraminidase gene. RESULTS: Increased levels of innate-immunity mediators (IP-10, MCP-1, MIP-1β), and the absence of anti-nvH1N1 antibodies, characterized the early response to nvH1N1 infection in both hospitalized and mild patients. High systemic levels of type-II interferon (IFN-γ) and also of a group of mediators involved in the development of T-helper 17 (IL-8, IL-9, IL-17, IL-6) and T-helper 1 (TNF-α, IL-15, IL-12p70) responses were exclusively found in hospitalized patients. IL-15, IL-12p70, IL-6 constituted a hallmark of critical illness in our study. A significant inverse association was found between IL-6, IL-8 and PaO2 in critical patients. CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. The exact role of Th1 and Th17 mediators in the evolution of nvH1N1 mild and severe disease merits further investigation as to the detrimental or beneficial role these cytokines play in severe illness. |
format | Text |
id | pubmed-2811892 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28118922010-01-28 Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza Bermejo-Martin, Jesus F Ortiz de Lejarazu, Raul Pumarola, Tomas Rello, Jordi Almansa, Raquel Ramírez, Paula Martin-Loeches, Ignacio Varillas, David Gallegos, Maria C Serón, Carlos Micheloud, Dariela Gomez, Jose Manuel Tenorio-Abreu, Alberto Ramos, María J Molina, M Lourdes Huidobro, Samantha Sanchez, Elia Gordón, Mónica Fernández, Victoria del Castillo, Alberto Marcos, Ma Ángeles Villanueva, Beatriz López, Carlos Javier Rodríguez-Domínguez, Mario Galan, Juan-Carlos Cantón, Rafael Lietor, Aurora Rojo, Silvia Eiros, Jose M Hinojosa, Carmen Gonzalez, Isabel Torner, Nuria Banner, David Leon, Alberto Cuesta, Pablo Rowe, Thomas Kelvin, David J Crit Care Research INTRODUCTION: Human host immune response following infection with the new variant of A/H1N1 pandemic influenza virus (nvH1N1) is poorly understood. We utilize here systemic cytokine and antibody levels in evaluating differences in early immune response in both mild and severe patients infected with nvH1N1. METHODS: We profiled 29 cytokines and chemokines and evaluated the haemagglutination inhibition activity as quantitative and qualitative measurements of host immune responses in serum obtained during the first five days after symptoms onset, in two cohorts of nvH1N1 infected patients. Severe patients required hospitalization (n = 20), due to respiratory insufficiency (10 of them were admitted to the intensive care unit), while mild patients had exclusively flu-like symptoms (n = 15). A group of healthy donors was included as control (n = 15). Differences in levels of mediators between groups were assessed by using the non parametric U-Mann Whitney test. Association between variables was determined by calculating the Spearman correlation coefficient. Viral load was performed in serum by using real-time PCR targeting the neuraminidase gene. RESULTS: Increased levels of innate-immunity mediators (IP-10, MCP-1, MIP-1β), and the absence of anti-nvH1N1 antibodies, characterized the early response to nvH1N1 infection in both hospitalized and mild patients. High systemic levels of type-II interferon (IFN-γ) and also of a group of mediators involved in the development of T-helper 17 (IL-8, IL-9, IL-17, IL-6) and T-helper 1 (TNF-α, IL-15, IL-12p70) responses were exclusively found in hospitalized patients. IL-15, IL-12p70, IL-6 constituted a hallmark of critical illness in our study. A significant inverse association was found between IL-6, IL-8 and PaO2 in critical patients. CONCLUSIONS: While infection with the nvH1N1 induces a typical innate response in both mild and severe patients, severe disease with respiratory involvement is characterized by early secretion of Th17 and Th1 cytokines usually associated with cell mediated immunity but also commonly linked to the pathogenesis of autoimmune/inflammatory diseases. The exact role of Th1 and Th17 mediators in the evolution of nvH1N1 mild and severe disease merits further investigation as to the detrimental or beneficial role these cytokines play in severe illness. BioMed Central 2009 2009-12-11 /pmc/articles/PMC2811892/ /pubmed/20003352 http://dx.doi.org/10.1186/cc8208 Text en Copyright ©2009 Bermejo-Martin et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Bermejo-Martin, Jesus F Ortiz de Lejarazu, Raul Pumarola, Tomas Rello, Jordi Almansa, Raquel Ramírez, Paula Martin-Loeches, Ignacio Varillas, David Gallegos, Maria C Serón, Carlos Micheloud, Dariela Gomez, Jose Manuel Tenorio-Abreu, Alberto Ramos, María J Molina, M Lourdes Huidobro, Samantha Sanchez, Elia Gordón, Mónica Fernández, Victoria del Castillo, Alberto Marcos, Ma Ángeles Villanueva, Beatriz López, Carlos Javier Rodríguez-Domínguez, Mario Galan, Juan-Carlos Cantón, Rafael Lietor, Aurora Rojo, Silvia Eiros, Jose M Hinojosa, Carmen Gonzalez, Isabel Torner, Nuria Banner, David Leon, Alberto Cuesta, Pablo Rowe, Thomas Kelvin, David J Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title | Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title_full | Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title_fullStr | Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title_full_unstemmed | Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title_short | Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza |
title_sort | th1 and th17 hypercytokinemia as early host response signature in severe pandemic influenza |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811892/ https://www.ncbi.nlm.nih.gov/pubmed/20003352 http://dx.doi.org/10.1186/cc8208 |
work_keys_str_mv | AT bermejomartinjesusf th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT ortizdelejarazuraul th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT pumarolatomas th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT rellojordi th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT almansaraquel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT ramirezpaula th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT martinloechesignacio th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT varillasdavid th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT gallegosmariac th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT seroncarlos th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT michelouddariela th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT gomezjosemanuel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT tenorioabreualberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT ramosmariaj th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT molinamlourdes th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT huidobrosamantha th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT sanchezelia th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT gordonmonica th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT fernandezvictoria th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT delcastilloalberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT marcosmaangeles th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT villanuevabeatriz th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT lopezcarlosjavier th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT rodriguezdominguezmario th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT galanjuancarlos th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT cantonrafael th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT lietoraurora th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT rojosilvia th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT eirosjosem th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT hinojosacarmen th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT gonzalezisabel th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT tornernuria th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT bannerdavid th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT leonalberto th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT cuestapablo th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT rowethomas th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza AT kelvindavidj th1andth17hypercytokinemiaasearlyhostresponsesignatureinseverepandemicinfluenza |